Results 11 to 20 of about 3,931 (193)

Extracorporeal photopheresis in stiff person syndrome [PDF]

open access: yesFrontiers in Immunology
Yandy Marx Castillo-Aleman   +1 more
doaj   +4 more sources

Extracorporeal Photopheresis—An Overview

open access: yesFrontiers in Medicine, 2018
Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of cutaneous T-cell lymphoma (CTCL) in 1988.
Ara Cho   +2 more
doaj   +3 more sources

Advances in extracorporeal photopheresis

open access: yesZhongguo shuxue zazhi, 2022
Extracorporeal photopheresis(ECP) is a bidirectional cellular immunomodulatory therapy based on leukapheresis, which can mediate not only immunopotentiation but also immunosuppression.
Zhanrui CHENG   +3 more
doaj   +2 more sources

Fotoferese extracorpórea Extracorporeal photopheresis

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2008
Fotoferese extracorpórea é uma modalidade de terapia celular que tem demonstrado eficácia e segurança em pacientes portadores de doenças auto-imunes e mediadas por células T, incluindo esclerodermia, linfoma de células T cutâneo/ Síndrome de Sézary e ...
Márcia M. Silva   +1 more
doaj   +2 more sources

Extracorporeal photopheresis: Review of technical aspects

open access: yesAsian Journal of Transfusion Science, 2017
Extracorporeal photochemotherapy (ECP) is considered as an immune modulating therapy majorly targeting the T cells of the Immune system. ECP induces an anti-inflammatory condition with tolerogenic responses without inducing a global immunosuppression ...
Satyam Arora, Rasika Setia
doaj   +3 more sources

Extracorporeal photopheresis and renal transplantation

open access: yesNefrología (English Edition), 2020
Saulo Fernández Granados   +8 more
doaj   +3 more sources

Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria. [PDF]

open access: yesJ Clin Apher
ABSTRACT Chronic graft‐versus‐host disease (cGVHD) remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Many cGVHD patients require prolonged systemic immunosuppression with corticosteroids, which carry significant adverse effects, and alternative therapies are often required.
Goretsky Y   +18 more
europepmc   +2 more sources

Treatment of graft versus host disease with photopheresis interferes in voriconazole therapeutic drug monitoring: A case study

open access: yesPractical Laboratory Medicine, 2023
Extracorporeal photopheresis is an established procedure for refractory graft-versus-host disease, a major complication associated with notable morbidity and mortality in patients with allogeneic hematopoietic stem cell transplant.
Adriana Sassone   +4 more
doaj   +1 more source

Extracorporeal Therapy in Dermatology

open access: yesIndian Journal of Dermatology, 2021
Extracorporeal therapy is a treatment modality where human blood undergoes favorable technical modifications and is reintroduced into the same patient.
Sumit Sen   +2 more
doaj   +1 more source

Psoralen and ultraviolet A light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing [PDF]

open access: yes, 2016
Psoralen and ultraviolet A light (PUNTA) are used to kill pathogens in blood products and as a treatment of aberrant cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft versus-host disease.
Compernolle, Veerle   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy